The perioperative anaesthetic management and outcomes of COVID-19 associated mucormycosis patients
暂无分享,去创建一个
[1] Sam T. Mathew,et al. COVID-19–associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India , 2021, PLoS neglected tropical diseases.
[2] I. Konaté,et al. QSIRS Can Improve Accuracy of QSOFA and SIRS in Prediction of Mortality in Surgical Emergencies , 2021, The Surgery Journal.
[3] K. Gupta,et al. Anaesthetic considerations for post-COVID-19 mucormycosis surgery- A case report and review of literature , 2021, Indian journal of anaesthesia.
[4] Shuchita Singh,et al. Rhino-orbital mucormycosis in a COVID-19 patient , 2021, BMJ Case Reports.
[5] Kipp W. Johnson,et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection , 2020, Journal of the American College of Cardiology.
[6] H. Shan,et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase , 2020, Respiratory Research.
[7] J. Zahar,et al. Invasive fungal diseases during COVID-19: We should be prepared , 2020, Journal de Mycologie Médicale.
[8] S. Bajwa,et al. Peri-operative and critical care concerns in coronavirus pandemic , 2020, Indian journal of anaesthesia.
[9] E. Karaaslan. Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on challenges. , 2019, Journal de mycologie medicale.
[10] Elizabeth W. Duggan,et al. Perioperative Hyperglycemia Management: An Update , 2017, Anesthesiology.